Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial

C. Male*, A.W.A. Lensing, J.S. Palumbo, R. Kumar, I. Nurmeev, K. Hege, D. Bonnet, P. Connor, H.L. Hooimeijer, M. Torres, A.K.C. Chan, G. Kenet, S. Holzhauer, A. Santamaria, P. Amedro, E. Chalmers, P. Simioni, R.V. Bhat, D.L. Yee, O. LvovaJ. Beyer-Westendorf, T.T. Biss, I. Martinelli, P. Saracco, M. Peters, K. Kallay, C.A. Gauger, M.P. Massicotte, G. Young, A.F. Pap, M. Majumder, W.T. Smith, J.F. Heubach, S.D. Berkowitz, K. Thelen, D. Kubitza, M. Crowther, M.H. Prins, P. Monagle, EINSTEIN-Jr Phase 3 Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

70 Citations (Web of Science)
Original languageEnglish
Pages (from-to)E18-E27
Number of pages10
JournalThe Lancet Haematology
Volume7
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • definition
  • disease
  • oral rivaroxaban
  • thrombosis
  • DEFINITION
  • ORAL RIVAROXABAN
  • THROMBOSIS
  • DISEASE

Cite this